Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Derksen

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
European Journal of Medicinal Chemistry|September 10, 2015
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonistsJoakim E Swedberg, Christina I Schroeder, Justin M Mitchell, et al.
European Journal of Medicinal Chemistry|November 9, 2016
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signalingFabien Plisson, Timothy A Hill, Justin M Mitchell, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2013
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemiaBenjamin D Stevens, John Litchfield, Jeffrey A Pfefferkorn, et al.
Journal of Medicinal Chemistry|April 4, 2015
Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) AgonistsHuy N Hoang, Kun Song, Timothy A Hill, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Journal of Medicinal Chemistry|June 1, 2022
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 ReceptorDavid A Griffith, David J Edmonds, Jean-Philippe Fortin, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
European Journal of Medicinal Chemistry|September 10, 2015
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonistsJoakim E Swedberg, Christina I Schroeder, Justin M Mitchell, et al.
European Journal of Medicinal Chemistry|November 9, 2016
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signalingFabien Plisson, Timothy A Hill, Justin M Mitchell, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2013
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemiaBenjamin D Stevens, John Litchfield, Jeffrey A Pfefferkorn, et al.
Journal of Medicinal Chemistry|April 4, 2015
Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) AgonistsHuy N Hoang, Kun Song, Timothy A Hill, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Journal of Medicinal Chemistry|June 1, 2022
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 ReceptorDavid A Griffith, David J Edmonds, Jean-Philippe Fortin, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 4